Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Open access

Abstract

There is an urgent need for first-line treatment options for patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Claudin-18 isoform 2 (CLDN18.2) is expressed in normal gastric cells and maintained in malignant G/GEJ adenocarcinoma cells. GLOW (closed enrollment), a global, double-blind, phase 3 study, examined zolbetuximab, a monoclonal antibody that targets CLDN18.2, plus capecitabine and oxaliplatin (CAPOX) as first-line treatment for CLDN18.2-positive, HER2-negative, locally advanced unresectable or mG/GEJ adenocarcinoma. Patients ( n = 507) were randomized 1:1 (block sizes of two) to zolbetuximab plus CAPOX or placebo plus CAPOX. GLOW met the primary endpoint of progression-free survival (median, 8.21 months versus 6.80 months with zolbetuximab versus placebo; hazard ratio (HR) = 0.687; 95% confidence interval (CI), 0.544–0.866; P = 0.0007) and key secondary endpoint of overall survival (median, 14.39 months versus 12.16 months; HR = 0.771; 95% CI, 0.615–0.965; P = 0.0118). Grade ≥3 treatment-emergent adverse events were similar with zolbetuximab (72.8%) and placebo (69.9%). Zolbetuximab plus CAPOX represents a potential new first-line therapy for patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or mG/GEJ adenocarcinoma. ClinicalTrials.gov identifier: NCT03653507 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02465-7

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CONSORT diagram of GLOW study. a‘CLDN18.2-positive’ was defined as ≥75% of tumor cells with moderate-to-strong membranous CLDN18 staining as determined by central immunohistochemistry using the investigational VENTANA CLDN18 (43-14A) RxDx Assay. b‘Other’ represents patients whose tumors were CLDN18.2-positive but failed screening for other reasons, including laboratory findings, HER2 expression status, Eastern Cooperative Oncology Group (ECOG) performance status score, other exclusion criteria or withdrawal by patient. cIf patients discontinued from both zolbetuximab or placebo and CAPOX on the same day, all reasons for discontinuation were summarized; the sum of values for individual reasons for discontinuation is more than 212 for the zolbetuximab group and more than 213 for the placebo group. dOne patient randomized to the placebo plus CAPOX group received one dose of zolbetuximab as a protocol deviation and was moved to the zolbetuximab plus CAPOX group for the safety analysis set.
Fig. 1 CONSORT diagram of GLOW study. a‘CLDN18.2-positive’ was defined as ≥75% of tumor cells with moderate-to-strong membranous CLDN18 staining as determined by central immunohistochemistry using the investigational VENTANA CLDN18 (43-14A) RxDx Assay. b‘Other’ represents patients whose tumors were CLDN18.2-positive but failed screening for other reasons, including laboratory findings, HER2 expression status, Eastern Cooperative Oncology Group (ECOG) performance status score, other exclusion criteria or withdrawal by patient. cIf patients discontinued from both zolbetuximab or placebo and CAPOX on the same day, all reasons for discontinuation were summarized; the sum of values for individual reasons for discontinuation is more than 212 for the zolbetuximab group and more than 213 for the placebo group. dOne patient randomized to the placebo plus CAPOX group received one dose of zolbetuximab as a protocol deviation and was moved to the zolbetuximab plus CAPOX group for the safety analysis set.CC BY · PubMed Central
Fig. 2 PFS in the ITT population. a, Kaplan–Meier PFS curves of all patients. b, Forest plots of PFS by subgroups.
Fig. 2 PFS in the ITT population. a, Kaplan–Meier PFS curves of all patients. b, Forest plots of PFS by subgroups.CC BY · PubMed Central
Fig. 3 OS in the ITT population. a, Kaplan–Meier OS curves of all patients. b, Forest plots of OS by subgroups.
Fig. 3 OS in the ITT population. a, Kaplan–Meier OS curves of all patients. b, Forest plots of OS by subgroups.CC BY · PubMed Central
Extended Data Fig. 1 PFS in the ITT population by investigator. Kaplan-Meier curve of PFS in all patients. CAPOX, capecitabine plus oxaliplatin regimen; CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat; mo., months; No., number; PFS, progression-free survival.
Extended Data Fig. 1 PFS in the ITT population by investigator. Kaplan-Meier curve of PFS in all patients. CAPOX, capecitabine plus oxaliplatin regimen; CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat; mo., months; No., number; PFS, progression-free survival.CC BY · PubMed Central
Extended Data Fig. 2 First occurrence of nausea and vomiting in the safety analysis set. Events were counted if they did not occur in any previous onset interval. Individual data points are reported in Supplementary Tables 3 and 4. aThe onset day in the onset interval was defined as the date of onset minus the date of first dose plus 1. CAPOX, capecitabine plus oxaliplatin regimen.
Extended Data Fig. 2 First occurrence of nausea and vomiting in the safety analysis set. Events were counted if they did not occur in any previous onset interval. Individual data points are reported in Supplementary Tables 3 and 4. aThe onset day in the onset interval was defined as the date of onset minus the date of first dose plus 1. CAPOX, capecitabine plus oxaliplatin regimen.CC BY · PubMed Central
Extended Data Fig. 3 All occurrence of nausea and vomiting in the safety analysis set. Individual data points are reported in Supplementary Tables 5 and 6. aThe onset day in the onset interval was defined as the date of onset minus the date of first dose plus 1. CAPOX, capecitabine plus oxaliplatin regimen.
Extended Data Fig. 3 All occurrence of nausea and vomiting in the safety analysis set. Individual data points are reported in Supplementary Tables 5 and 6. aThe onset day in the onset interval was defined as the date of onset minus the date of first dose plus 1. CAPOX, capecitabine plus oxaliplatin regimen.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 688

Metadata

Authors
Shah, M. A., Shitara, K., Ajani, J. A., Bang, Y.-J., Enzinger, P., Ilson, D., Lordick, F., Van Cutsem, E., Gallego Plazas, J., Huang, J., Shen, L., Oh, S. C., Sunpaweravong, P., Soo Hoo, H. F., Turk, H. M., Oh, M., Park, J. W., Moran, D., Bhattacharya, P., Arozullah, A., & Xu, R.-H.
Affiliations
  • Weill Cornell Medicine (US)
  • National Cancer Center Hospital East (JP)
  • The University of Texas MD Anderson Cancer Center (US)
  • Seoul National University (KR)
  • Dana-Farber Cancer Institute (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • University Hospital Leipzig (DE)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Peking University Cancer Hospital (CN)
  • Korea University Guro Hospital (KR)
  • Prince of Songkla University (TH)
  • Astellas Pharma (United States) (US)
  • Sun Yat-sen University (CN)
Corresponding author
Xu, Rui-Hua
Venue
Nature Medicine
Published
2023-07-31
Volume
29
Issue
8
Pages
2133-2141
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4385429828
Cited by
681
References
35
Citations by year
2026: 274 · 2025: 221 · 2024: 162 · 2023: 24
FWCI
125.47
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion, cc-by)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
  • Greater South Information System
Funders
Astellas Pharma Inc.
Topics
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
zolbetuximab, CLDN18.2, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, HER2-negative, capecitabine, oxaliplatin, XELOX, first-line therapy, progression-free survival, overall survival, monoclonal antibodies
MeSH terms
Capecitabine, Oxaliplatin, Adenocarcinoma, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Esophagogastric Junction, Humans, Stomach Neoplasms, Claudins, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. https://app.cochat.ai/papers/10.1038/s41591-023-02465-7
The paper
Shah, M. A., Shitara, K., Ajani, J. A., Bang, Y.-J., Enzinger, P., Ilson, D., Lordick, F., Van Cutsem, E., Gallego Plazas, J., Huang, J., Shen, L., Oh, S. C., Sunpaweravong, P., Soo Hoo, H. F., Turk, H. M., Oh, M., Park, J. W., Moran, D., Bhattacharya, P., . . . Xu, R.-H. (2023). Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02465-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.